GI Oncology
Conference Coverage
Nivolumab shows promise for pretreated advanced HCC
SAN FRANCISCO – Nivolumab was associated with durable responses in heavily pretreated patients with advanced hepatocellular carcinoma in the dose-...
Conference Coverage
Adjuvant GEMOX disappoints for localized biliary tract cancer
SAN FRANCISCO – Postsurgery adjuvant treatment with gemcitabine and oxaliplatin (GEMOX) was feasible, but failed to significantly improve relapse-...
Conference Coverage
Breath test aims to sniff out GEJ cancers
AMSTERDAM
Conference Coverage
Hand-foot syndrome less with S-1 than capecitabine in mCRC
AMSTERDAM – S-1 was associated with a lower incidence of hand-foot syndrome than was capecitabine in patients with metastatic colorectal cancer....
From the Journals
Endoscopic resection alone sufficed in many T1 colorectal cancers
Patients with T1 colorectal cancer might not benefit from additional surgery after endoscopic resection unless they have positive or indeterminate...
From the Journals
Adjuvant chemotherapy overused in young patients with colon cancer
Adjuvant chemotherapy may be overused among younger patients with colon cancer, without clear evidence of survival benefit over surgery alone.
From the Journals
Esophageal cancers: Apples and oranges wrongly lumped together
Genomic analysis suggests esophageal adenocarcinoma and esophageal squamous cell carcinoma are two separate diseases that should not be combined...
From the Journals
177Lu-Dotatate for advanced midgut neuroendocrine tumors
177Lu-Dotatate, a radionuclide related to octreotide, reduced the risk of disease progression or death by 79% in a phase III trial involving 229...
From the Journals
Gastric cancer yields to growth hormone antagonist in lab
It sounds counterintuitive, but targeting a neuropeptide hormone produced in the hypothalamus may be an effective strategy for treating gastric...
From the Journals
Mutations missed in early-onset colorectal cancer
As many as one in six patients with early-onset colorectal cancer have a pathogenic genetic mutation, but around one-third of these patients may...
From the Journals
VIDEO: Y90 radioembolization beat chemoembolization in liver cancer
Liver cancer took nearly four times longer to progress after yttrium-90 radioembolization than after conventional transarterial chemoembolization...